Abstract:Background/objective: Neurostimulants may improve or accelerate cognitive and functional recovery after intracerebral hemorrhage (ICH), ischemic stroke (IS), or subarachnoid hemorrhage (SAH), but few studies have described their safety and effectiveness in the intensive care unit (ICU). The objective of this study was to describe amantadine and modafinil administration practices during acute stroke care starting in the ICU and to evaluate safety and effectiveness. Methods: Consecutive adult ICU patients treated with amantadine and/or modafinil following acute non-traumatic IS, ICH, or SAH were evaluated. Neurostimulant administration data were extracted from the electronic medication administration record, including medication (amantadine, modafinil, or both), starting dose, time from stroke to initiation, and whether the neurostimulant was continued at hospital discharge. Patients were considered responders if they met two of three criteria within 9 days of neurostimulant initiation: increase in Glasgow coma scale (GCS) score ≥ 3 points from pre-treatment baseline, improved wakefulness or participation documented in caregiver notes, or clinical improvement documented in physical or occupational therapy notes. Potential confounders of the effectiveness assessment and adverse drug effects were also recorded. Results: A total of 87 patients were evaluable during the 3.7-year study period, including 41 (47%) with ICH, 29 (33%) with IS, and 17 (20%) with SAH. The initial neurostimulant administered was amantadine in 71 (82%) patients, modafinil in 13 (15%), or both in 3 (3%) patients. Neurostimulants were initiated a median of 7 (4.25, 12.75) days post-stroke (range 1-27 days) for somnolence (77%), not following commands (32%), lack of eye opening (28%), or low GCS (17%). The most common starting dose was 100 mg twice daily for both amantadine (86%) and modafinil (54%). Of the 79 patients included in the effectiveness evaluation, 42 (53%) were considered responders, including 34/62 (55%) receiving amantadine monotherapy and 8/24 (33%) receiving both amantadine and modafinil at the time they met the definition of a responder. No patient receiving modafinil monotherapy was considered a responder. The median time from initiation to response was 3 (2, 5) days. Responders were more frequently discharged home or to acute rehabilitation compared to non-responders (90% vs 62%, p = 0.006). Among survivors, 63/72 (88%) were prescribed a neurostimulant at hospital discharge. The most common potential adverse drug effect was sleep disruption (16%). Conclusions: Neurostimulant administration during acute stroke care may improve wakefulness. Future controlled studies with a neurostimulant administration protocol, prospective evaluation, and discretely defined response and safety criteria are needed to confirm these encouraging findings.

The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage

Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: A retrospective controlled study

Application value of acupuncture combined with conventional Western medicine in postoperative treatment of patients with critical cerebral hemorrhage

Efficacy of Melatonin for Prolonged Disorders of Consciousness: a Double-Blind, Randomized Clinical Trial

Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury

Early Amantadine Treatment Reduces the Risk of Death in Patients with Large Hemisphere Infarctions:A Chinese Hospital-Based Study

Spontaneous Recovery from Unresponsive Wakefulness Syndrome to a Minimally Conscious State: Early Structural Changes Revealed by 7-T Magnetic Resonance Imaging.

Early Amantadine Treatment Reduces the Risk of Death in Patients With Large Hemisphere Infarctions

Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness

Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients

The effect of amantadine treatment on neurological outcome and mortality in mechanically ventilated severe head trauma patients in intensive care unit

Informing future randomized controlled trials of amantadine hydrochloride in neurocritical care and post-neurocritical care stroke patients through a retrospective study

Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study

Randomized Controlled Trial of Early Rehabilitation after Intracerebral Hemorrhage Stroke

Amantadine for Traumatic Brain Injury—Supporting Evidence and Mode of Action

Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats

The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial

Modafinil therapy and mental status following aneurysmal subarachnoid hemorrhage: comprehensive stroke-center analysis

Amantadine and memantine: a comprehensive review for acquired brain injury

Edaravone use in acute intracerebral hemorrhage: A systematic review and meta-analysis of randomized controlled trials

Abstract 2: Intracranial Hemorrhage Managed By A Mobile Stroke Unit